Here are the 10-K annual reports from Halozyme Therapeutics, Inc. (HALO) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow HALO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HALO filings page.
Halozyme Therapeutics, Inc. presents an annual overview of its business focused on drug-delivery technologies that convert intravenous therapies to subcutaneous injections. The company’s ENHANZE platform, based on its rHuPH20 enzyme, is widely licensed to major biopharma partners, generating upfront fees, milestones, bulk enzyme sales and royalties from ten commercial products.
Halozyme also develops Hypercon and Surf Bio hyperconcentration technologies and pressure-assisted auto-injectors, plus proprietary products Hylenex and XYOSTED. It highlights extensive global partnerships with Roche, Takeda, Janssen, argenx, BMS and others, alongside detailed risk factors spanning regulatory approval, supply chain, competition, financing, cybersecurity and market volatility.